Foghorn Therapeutics Inc. provided a financial update for the full year ended December 31, 2024, reporting a strong balance sheet. As of year-end, the company held $243.7 million in cash, cash equivalents, and marketable securities. This capital is projected to fund its operating expenses and capital expenditure requirements into 2027.
The company highlighted continued progress in its pipeline, with the Phase 1 trial of FHD-909, a first-in-class oral selective SMARCA2 inhibitor for SMARCA4 mutated cancers, enrolling well. Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors is slated for presentation at the AACR 2025 meeting.
Foghorn also announced achieving selective degradation of ARID1B, with a program update expected later in 2025. Furthermore, the Selective CBP degrader and Selective EP300 degrader programs are continuing to advance towards IND filings, demonstrating ongoing productivity from the Gene Traffic Control platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.